Guerbet Reports 2025 Revenue Decline Amid Raleigh Site Challenges
Event summary
- Guerbet's 2025 revenue fell 3.5% at constant exchange rates to €786.4 million, missing the forecasted range of -4% to -5%.
- Q4 revenue declined 5.6% due to operational issues at the Raleigh site in the U.S.
- EBITDA margin forecast confirmed at 10.5%-12%, with free cash flow now expected to be positive.
- 2026 revenue and profitability expected to be impacted by ongoing Raleigh site compliance issues.
The big picture
Guerbet's revenue decline reflects broader challenges in the medical imaging sector, particularly around regulatory compliance and supply chain disruptions. The company's ability to navigate these issues will be critical as it transitions under new leadership, with the impact of the Raleigh site set to shape its financial trajectory in 2026. The positive free cash flow revision suggests some operational improvements, but sustained performance will depend on resolving the site's compliance issues.
What we're watching
- Regulatory Compliance
- How the ongoing compliance plan at the Raleigh site will affect Guerbet's operational efficiency and regulatory standing.
- Financial Performance
- Whether Guerbet can sustain positive free cash flow amid revenue pressures in 2026.
- Market Dynamics
- The pace at which Guerbet can recover lost market share in key regions like France and Asia.
Related topics